Literature DB >> 16633908

Benign epithelial ovarian tumours-cancer precursors or markers for ovarian cancer risk?

Susan Jordan1, Adèle Green, Penelope Webb.   

Abstract

The natural history of the development of epithelial ovarian cancer remains obscure and no effective screening test exists. In several human malignancies progression from benign to invasive tumour occurs, but this sequence has not been established for epithelial ovarian cancer. We have reviewed epidemiological, histopathological and molecular studies of benign epithelial ovarian tumours to assess the evidence for and against such a progression in ovarian cancer. These data suggest that a diagnosis of a benign ovarian cyst or tumour is associated with an increased risk of ovarian cancer later in life. Current evidence also suggests that benign serous tumours can progress to low-grade serous cancer and that benign mucinous tumours can progress to mucinous cancer. The more common high-grade serous ovarian cancers are likely to arise de novo.

Entities:  

Mesh:

Year:  2006        PMID: 16633908     DOI: 10.1007/s10552-005-0370-y

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  9 in total

Review 1.  Molecular pathogenesis of endometrial and ovarian cancer.

Authors:  Melissa A Merritt; Daniel W Cramer
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

2.  Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer.

Authors:  Xiangxiang Bao; Shan Zhao; Ting Liu; Yang Liu; Yueyang Liu; Xingsheng Yang
Journal:  J Histochem Cytochem       Date:  2013-01-04       Impact factor: 2.479

3.  Long and irregular menstrual cycles, polycystic ovary syndrome, and ovarian cancer risk in a population-based case-control study.

Authors:  H R Harris; L J Titus; D W Cramer; K L Terry
Journal:  Int J Cancer       Date:  2016-10-06       Impact factor: 7.396

4.  Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery.

Authors:  Mary Anne Rossing; Kara L Cushing-Haugen; Kristine G Wicklund; Jennifer A Doherty; Noel S Weiss
Journal:  Cancer Causes Control       Date:  2008-08-14       Impact factor: 2.506

5.  Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium.

Authors:  Catherine M Olsen; Christina M Nagle; David C Whiteman; Roberta Ness; Celeste Leigh Pearce; Malcolm C Pike; Mary Anne Rossing; Kathryn L Terry; Anna H Wu; Harvey A Risch; Herbert Yu; Jennifer A Doherty; Jenny Chang-Claude; Rebecca Hein; Stefan Nickels; Shan Wang-Gohrke; Marc T Goodman; Michael E Carney; Rayna K Matsuno; Galina Lurie; Kirsten Moysich; Susanne K Kjaer; Allan Jensen; Estrid Hogdall; Ellen L Goode; Brooke L Fridley; Robert A Vierkant; Melissa C Larson; Joellen Schildkraut; Cathrine Hoyo; Patricia Moorman; Rachel P Weber; Daniel W Cramer; Allison F Vitonis; Elisa V Bandera; Sara H Olson; Lorna Rodriguez-Rodriguez; Melony King; Louise A Brinton; Hannah Yang; Montserrat Garcia-Closas; Jolanta Lissowska; Hoda Anton-Culver; Argyrios Ziogas; Simon A Gayther; Susan J Ramus; Usha Menon; Aleksandra Gentry-Maharaj; Penelope M Webb
Journal:  Endocr Relat Cancer       Date:  2013-03-22       Impact factor: 5.678

6.  Role of dihydrotestosterone (DHT) on TGF-β1 signaling pathway in epithelial ovarian cancer cells.

Authors:  Karla Kohan-Ivani; Fernando Gabler; Alberto Selman; Margarita Vega; Carmen Romero
Journal:  J Cancer Res Clin Oncol       Date:  2015-06-20       Impact factor: 4.553

Review 7.  Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review.

Authors:  Holly R Harris; Kathryn L Terry
Journal:  Fertil Res Pract       Date:  2016-12-05

Review 8.  Screening, epidemiology, molecular biology, and treatment strategies for endometriosis-associated ovarian cancer.

Authors:  Hiroshi Kobayashi
Journal:  Reprod Med Biol       Date:  2009-09-26

9.  Overexpression of TROP2 promotes proliferation and invasion of ovarian cancer cells.

Authors:  Bin Wu; Chunli Yu; Bin Zhou; Tingting Huang; Lei Gao; Tao Liu; Xingsheng Yang
Journal:  Exp Ther Med       Date:  2017-07-12       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.